|
Gene: VGLL1 |
Gene summary for VGLL1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | VGLL1 | Gene ID | 51442 |
Gene name | vestigial like family member 1 | |
Gene Alias | TDU | |
Cytomap | Xq26.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q99990 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51442 | VGLL1 | P8T-E | Human | Esophagus | ESCC | 3.88e-09 | 3.19e-01 | 0.0889 |
51442 | VGLL1 | P39T-E | Human | Esophagus | ESCC | 3.60e-13 | 5.82e-01 | 0.0894 |
51442 | VGLL1 | P74T-E | Human | Esophagus | ESCC | 1.96e-03 | 2.21e-01 | 0.1479 |
51442 | VGLL1 | P82T-E | Human | Esophagus | ESCC | 1.13e-10 | 9.94e-01 | 0.1072 |
51442 | VGLL1 | P84T-E | Human | Esophagus | ESCC | 8.33e-03 | 4.18e-01 | 0.0933 |
51442 | VGLL1 | P127T-E | Human | Esophagus | ESCC | 8.31e-06 | 2.35e-01 | 0.0826 |
51442 | VGLL1 | P130T-E | Human | Esophagus | ESCC | 8.96e-45 | 1.14e+00 | 0.1676 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VGLL1 | SNV | Missense_Mutation | novel | c.189N>T | p.Gln63His | p.Q63H | Q99990 | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
VGLL1 | SNV | Missense_Mutation | c.290N>C | p.Asn97Thr | p.N97T | Q99990 | protein_coding | tolerated(0.19) | benign(0.038) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD | |
VGLL1 | SNV | Missense_Mutation | rs138345606 | c.656N>A | p.Arg219His | p.R219H | Q99990 | protein_coding | tolerated(0.93) | benign(0.003) | TCGA-18-4721-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
VGLL1 | SNV | Missense_Mutation | novel | c.739N>T | p.His247Tyr | p.H247Y | Q99990 | protein_coding | tolerated_low_confidence(1) | benign(0.001) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
VGLL1 | SNV | Missense_Mutation | novel | c.451N>T | p.Pro151Ser | p.P151S | Q99990 | protein_coding | tolerated(0.56) | benign(0.023) | TCGA-22-4594-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
VGLL1 | SNV | Missense_Mutation | novel | c.103N>A | p.Gly35Arg | p.G35R | Q99990 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-56-7731-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VGLL1 | SNV | Missense_Mutation | rs768578233 | c.556N>A | p.Ala186Thr | p.A186T | Q99990 | protein_coding | tolerated(0.71) | benign(0) | TCGA-66-2789-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
VGLL1 | SNV | Missense_Mutation | novel | c.484N>A | p.Asp162Asn | p.D162N | Q99990 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-77-7338-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
VGLL1 | SNV | Missense_Mutation | c.118N>T | p.Val40Leu | p.V40L | Q99990 | protein_coding | deleterious(0.02) | possibly_damaging(0.75) | TCGA-98-7454-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
VGLL1 | SNV | Missense_Mutation | novel | c.167N>C | p.Gln56Pro | p.Q56P | Q99990 | protein_coding | deleterious(0) | possibly_damaging(0.564) | TCGA-L3-A524-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |